Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004-2013.

Global Emergence and Dissemination of Enterococci as Nosocomial Pathogens: Attack of the Clones? Front Microbiol (2016) 1.03

Fluorocycline TP-271 Is Potent against Complicated Community-Acquired Bacterial Pneumonia Pathogens. mSphere (2017) 0.82

In vitro selection of Staphylococcus aureus mutants resistant to tigecycline with intermediate susceptibility to vancomycin. Ann Clin Microbiol Antimicrob (2016) 0.76

Prescription Patterns for Tigecycline in Severely Ill Patients for Non-FDA Approved Indications in a Developing Country: A Compromised Outcome. Front Microbiol (2017) 0.75

Tigecycline non-susceptibility occurs exclusively in fluoroquinolone-resistant Escherichia coli clinical isolates, including the major multidrug-resistant lineages O25b:H4-ST131-H30R and O1-ST648. Antimicrob Agents Chemother (2016) 0.75

Global Assessment of the Activity of Tigecycline against Multidrug-Resistant Gram-Negative Pathogens between 2004 and 2014 as Part of the Tigecycline Evaluation and Surveillance Trial. mSphere (2017) 0.75

Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial. Ann Clin Microbiol Antimicrob (2017) 0.75

Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev (2012) 5.65

Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother (2009) 3.63

Global spread of antibiotic resistance: the example of New Delhi metallo-β-lactamase (NDM)-mediated carbapenem resistance. J Med Microbiol (2013) 2.22

Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). J Antimicrob Chemother (2011) 2.01

The global spread of healthcare-associated multidrug-resistant bacteria: a perspective from Asia. Clin Infect Dis (2013) 1.55

Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria. Clin Microbiol Infect (2012) 1.54

A Review of Ten Years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011. Pharmaceuticals (Basel) (2013) 1.43

Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012. Int J Antimicrob Agents (2014) 1.22

Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011). Diagn Microbiol Infect Dis (2012) 1.21

Klebsiella pneumoniae antimicrobial drug resistance, United States, 1998-2010. Emerg Infect Dis (2013) 1.08

Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002-2010. Int J Antimicrob Agents (2013) 1.08

In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: tigecycline Evaluation and Surveillance Trial 2004 to 2007. Diagn Microbiol Infect Dis (2009) 1.06

Antimicrobial activity of daptomycin tested against Gram-positive pathogens collected in Europe, Latin America, and selected countries in the Asia-Pacific Region (2011). Diagn Microbiol Infect Dis (2013) 1.05

Acinetobacter baumannii infections in a tertiary care hospital in Mexico over the past 13 years. Chemotherapy (2013) 0.97

Limiting and controlling carbapenem-resistant Klebsiella pneumoniae. Infect Drug Resist (2013) 0.94

Emergence and dissemination of antibiotic resistance: a global problem. Indian J Med Microbiol (2012) 0.92

Trends in antibiotic resistance over time among pathogens from Canadian hospitals: results of the CANWARD study 2007-11. J Antimicrob Chemother (2013) 0.91

Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012). Antimicrob Agents Chemother (2014) 0.87

Surveillance programmes and antibiotic resistance: worldwide and regional monitoring of antibiotic resistance trends. Handb Exp Pharmacol (2012) 0.87

A longitudinal assessment of antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) in France between 2004 and 2012. Antimicrob Resist Infect Control (2014) 0.82

How to measure and monitor antimicrobial consumption and resistance. Enferm Infecc Microbiol Clin (2013) 0.79